Search

Your search keyword '"Pageaux, G.-P."' showing total 295 results
Start Over Author "Pageaux, G.-P."
295 results on '"Pageaux, G.-P."'

51. Sustained Virologic Response to Daclatasvir and Sofosbuvir, with or without Ribavirin, among Patients in the French Daclatasvir ATU Programme Infected with HCV Genotypes 4, 5 and 6

Author

Hézode, C., primary, Abergel, A., additional, Chas, J., additional, Conti, F., additional, Cotte, L., additional, Tateo, M., additional, Alric, L., additional, Vergniol, J., additional, Tomei, C., additional, Bernard, P.-H., additional, Loustaud-Ratti, V., additional, Arpurt, J.-P., additional, Blaison, D., additional, Larrey, D., additional, Fedchuk, L., additional, Bennai, Y., additional, Filipovics, A., additional, Fontaine, H., additional, and Pageaux, G.-P., additional

Published
2016
Full Text
View/download PDF

52. Ledipasvir/Sofosbuvir in NS3/4A Protease Inhibitor-Experienced Subjects with HCV Genotype 1 and HIV-Co-Infection Final Results of the ANRS HC31 Softrih Study

Author

Rosenthal, E., primary, Fougerou-Leurent, C., additional, Renault, A., additional, Teicher, E., additional, Dominguez, S., additional, Naqvi, A., additional, Metivier, S., additional, Cotte, L., additional, Reynes, J., additional, Valantin, M.-A., additional, Leroy, V., additional, Pageaux, G.-P., additional, Pol, S., additional, Piroth, L., additional, Perre, P., additional, Morlat, P., additional, Salmon-Ceron, D., additional, Chas, J., additional, Jeantils, V., additional, de Truchis, P., additional, Allègre, T., additional, Dupon, M., additional, Raffi, F., additional, Yazdanpanah, Y., additional, Poizot-Martin, I., additional, Neau, D., additional, Girard, P.-M., additional, Zucman, D., additional, Garraffo, R., additional, Chevaliez, S., additional, Carrieri, P., additional, Aumaitre, H., additional, Lacombe, K., additional, Bailly, F., additional, Billaud, E., additional, Pailhé, A., additional, Amri, I., additional, Bourlière, M., additional, Bellissant, E., additional, and Molina, J.-M., additional

Published
2016
Full Text
View/download PDF

53. Impact of Direct Anti-Viral Agents on Inactivation/De-Listing of Liver Transplant Candidates Listed for Decompensated C Cirrhosis: A European Study

Author

Belli, L.S., primary, Berenguer, M., additional, Rockenschaub, S.-R., additional, Martini, S., additional, Morelli, C., additional, Donato, F., additional, Volpes, R., additional, Pageaux, G.-P., additional, Coilly, A., additional, Fagiuoli, S., additional, Cortesi, P., additional, and Duvoux, C., additional

Published
2016
Full Text
View/download PDF

54. Sofosbuvir-Based-Regimen for HCV Recurrence after Combined Liver-Kidney Transplantation : Results from the ANRS CO23 Cupilt Study

Author

Dharancy, S., primary, Coilly, A., additional, Fougerou-Leurent, C., additional, Duvoux, C., additional, Kamar, N., additional, Leroy, V., additional, Tran, A., additional, Houssel-Debry, P., additional, Canva, V., additional, Moreno, C., additional, Conti, F., additional, Dumortier, J., additional, Di Martino, V., additional, Radenne, S., additional, De Ledinghen, V., additional, D’Alteroche, L., additional, Silvain, C., additional, Besch, C., additional, Perré, P., additional, Botta-Fridlund, D., additional, Francoz, C., additional, Habersetzer, F., additional, Montialoux, H., additional, Abergel, A., additional, Debette-Gratien, M., additional, Rohel, A., additional, Vallée, J.C.D., additional, and Pageaux, G.-P., additional

Published
2016
Full Text
View/download PDF

55. Does Multiorgan Failure Impact Prognosis of Liver Transplantation in Patients with End-Stage Liver Disease? Results of a French Retrospective Multicenter Case-Control Study

Author

Artru, F., primary, Louvet, A., additional, Ruiz, I., additional, Levesque, E., additional, Labreuche, J., additional, Jaber, S., additional, Lassailly, G., additional, Dharancy, S., additional, Boleslawski, E., additional, Lebuffe, G., additional, Kipnis, E., additional, Ichai, P., additional, Coilly, A., additional, De Martin, E., additional, Vibert, E., additional, Herrerro, A., additional, Samuel, D., additional, Pageaux, G.-P., additional, Mathurin, P., additional, and Saliba, F., additional

Published
2016
Full Text
View/download PDF

60. FRI-141 - Macrotrabecular-massive hepatocellular carcinoma: a distinctive histological subtype with clinical relevance

Author

Ziol, M., Poté, N., Amaddeo, G., Laurent, A., Nault, J.C., Oberti, F., Costentin, C., Michalak, S., Mohamed, B., Francoz, C., Pageaux, G.-P., Ramos, J., Thomas, D., Luciani, A., Guiu, B., Vilgrain, V., Aubé, C., Derman, J., Charpy, C., Zucman-Rossi, J., Barget, N., Seror, O., Ganne-Carrié, N., Paradis, V., and Calderaro, J.

Published
2018
Full Text
View/download PDF

64. Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (Acetaminophen): The multinational case-population SALT study

Author

Gulmez, S.E. Larrey, D. Pageaux, G.-P. Lignot, S. Lassalle, R. Jové, J. Gatta, A. McCormick, P.A. Metselaar, H.J. Monteiro, E. Thorburn, D. Bernal, W. Zouboulis-Vafiadis, I. De Vries, C. Perez-Gutthann, S. Sturkenboom, M. Bénichou, J. Montastruc, J.-L. Horsmans, Y. Salvo, F. Hamoud, F. Micon, S. Droz-Perroteau, C. Blin, P. Moore, N.

Abstract

Background: Most NSAIDs are thought to be able to cause hepatic injury and acute liver failure (ALF), but the event rates of those leading to transplantation (ALFT) remain uncertain. Objectives: The aim of the study was to estimate population event rates for NSAID-associated ALFT Methods: This was a case-population study of ALFT in 57 eligible liver transplant centres in seven countries (France, Greece, Ireland, Italy, The Netherlands, Portugal and the UK). Cases were all adults registered from 2005 to 2007 for a liver transplant following ALFT without identified clinical aetiology, exposed to an NSAID or paracetamol (acetaminophen) within 30 days before the onset of clinical symptoms. NSAID and paracetamol population exposures were assessed using national sales data from Intercontinental Marketing Services (IMS). Risk was estimated as the rate of ALFT per million treatment-years (MTY). Results: In the 52 participating centres, 9479 patients were registered for transplantation, with 600 for ALFT, 301 of whom, without clinical aetiology, had been exposed to a drug within 30 days. Of these 301 patients, 40 had been exposed to an NSAID and 192 to paracetamol (81 of whom were without overdose). Event rates per MTY were 1.59 (95 % CI 1.1-2.2) for all NSAIDs pooled, 2.3 (95 % CI 1.2-3.9) for ibuprofen, 1.9 (95 % CI 0.8-3.7) for nimesulide, 1.6 (95 % CI 0.6-3.4) for diclofenac and 1.6 (95 % CI 0.3-4.5) for ketoprofen. For paracetamol, the event rate was 3.3 per MTY (95 % CI 2.6-4.1) without overdoses and 7.8 (95 % CI 6.8-9.0) including overdoses. Conclusions: ALF leading to registration for transplantation after exposure to an NSAID was rare, with no major difference between NSAID. Non-overdose paracetamol-exposed liver failure was twice more common than NSAID-exposed liver failure. © 2013 The Author(s).

Published
2013

65. Impact of tumour differentiation to select patients before liver transplantation for hepatocellular carcinoma

Author

Decaens, T., Roudot-Thoraval, F., Badran, H., Wolf, P., Francois Durand, Adam, R., Boillot, O., Vanlemmens, C., Gugenheim, J., Dharancy, S., Bernard, P. H., Boudjema, K., Calmus, Y., Hardwigsen, J., Ducerf, C., Pageaux, G. P., Hilleret, M. N., Chazouillères, O., Cherqui, D., Mallat, A., Duvoux, C., Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service de santé publique [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service de Chirurgie Générale et Transplantation Multi Organes, CHU Strasbourg, Chercheur indépendant, Rythmes Biologiques et Cancers, Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'anatomie pathologique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse, Unité de chronothérapie, Centre méditerranéen de médecine moléculaire (C3M), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département Digestif, Centre Hospitalier Universitaire de Nice (CHU Nice)-Hôpital de l'Archet, Service d'Hépato-Gastro-Entérologie, CHU Bordeaux [Bordeaux]-Hôpital Saint-André, Service de Chirurgie Hépatobiliaire et Digestive [Rennes] = Hepatobiliary and Digestive Surgery [Rennes], CHU Pontchaillou [Rennes], Foie, métabolismes et cancer, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Service de Chirurgie Digestive, Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Chirurgie, Assistance Publique - Hôpitaux de Marseille (APHM)-Hospices Civiles de Marseille-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Département de Gastroentérologie et hépatologie, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-Hôpital Michallon, Service de chirurgie digestive, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor, Service d'hépato-gastro-entérologie [APHP Henri Mondor], Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Hôpital Henri Mondor-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), and Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

Subjects
Male, Time Factors, MESH: Chi-Square Distribution, Kaplan-Meier Estimate, MESH: Risk Assessment, MESH: Proportional Hazards Models, Risk Factors, MESH: Liver Neoplasms, MESH: Risk Factors, MESH: Carcinoma, Hepatocellular, Milan criteria, MESH: Treatment Outcome, MESH: Middle Aged, liver transplantation, Liver Neoplasms, Cell Differentiation, hepatocellular carcinoma, Middle Aged, prognostic score, MESH: Predictive Value of Tests, MESH: Reproducibility of Results, Treatment Outcome, Female, France, MESH: Neoplasm Recurrence, Local, Algorithms, Adult, MESH: Cell Differentiation, MESH: Liver Transplantation, Carcinoma, Hepatocellular, MESH: Algorithms, Risk Assessment, Disease-Free Survival, Decision Support Techniques, Predictive Value of Tests, Humans, MESH: Patient Selection, MESH: Kaplan-Meier Estimate, Proportional Hazards Models, Retrospective Studies, Chi-Square Distribution, MESH: Humans, Patient Selection, MESH: Time Factors, Reproducibility of Results, MESH: Decision Support Techniques, MESH: Adult, MESH: Retrospective Studies, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, MESH: ROC Curve, MESH: Male, MESH: France, ROC Curve, MESH: Disease-Free Survival, Neoplasm Recurrence, Local, MESH: Female
Abstract

International audience; AIM: To generate a new score with improved accuracy compared with Milan criteria to select patients. PATIENTS: The training cohort comprised 373 patients transplanted for hepatocellular carcinoma (HCC) between 1988 and 1998 (cohort 1). An algorithm was derived from the analysis of patient data by the proportional hazard Cox regression model. The area under the receiver operating characteristic (AUROC) was used to determine a cut-off value. The validation cohort comprised 140 patients transplanted between 1999 and 2001 (cohort 2). RESULTS: Multivariate analysis identified three predictors of 5-year tumour-free survival: tumour differentiation (P=0.02), diameter (P

Published
2011
Full Text
View/download PDF

66. PRELIMINARY RESULTS OF THE STUDY OF ACUTE LIVER TRANSPLANT (SALT): NSAID EXPOSURE AND RISK OF ACUTE LIVER FAILURE LEADING TO TRANSPLANTATION IN 7 EUROPEAN COUNTRIES

Author

Thorburn, D. Gulmez, E. Lignot, S. Larrey, D. de Vries, C. Perez-Gutthann, S. Montastruc, J. L. Sturkenboom, M. and Benichou, J. Velo, G. Caputi, A. Salvo, F. Hamoud, F. and Micon, S. Lassalle, R. Jove, J. Pageaux, G. P. and Horsmans, Y. Bernuau, J. Bissoli, F. Stricker, B. Gatta, A. Monteiro, E. Vafiadis, I. McCormick, A. Metselaar, H. and Sen, E. Nightingale, A. Blin, P. Moore, N.

Published
2011

68. P0745 : EQ-5D utility index in French patients with chronic hepatits C (CHC) infection: severe comorbidities and perceived progression of CHC infection matter more than actual liver disease stage

Author

Schwarzinger, M., primary, Cossais, S., additional, Deuffic-Burban, S., additional, Pol, S., additional, Fontaine, H., additional, Larrey, D., additional, Pageaux, G.-P., additional, Canva, V., additional, Mathurin, P., additional, and Yazdanpanah, Y., additional

Published
2015
Full Text
View/download PDF

69. P1334 : A multicentre, randomised, open-label study comparing the efficacy and safety of two doses of Doxorubicin TransdrugTM to best standard of care in patients with advanced Hepatocellular Carcinoma (HCC) after sorafenib. The relive study

Author

Merle, P., primary, Pelletier, G., additional, Habersetzer, F., additional, Luca Frassineti, G., additional, Pageaux, G.-P., additional, Borbath, I., additional, Gérolami, R., additional, Sánchez Antolín, G., additional, Bronowicki, J.-P., additional, Horváth, Z., additional, Touchefeu, Y., additional, Maieron, A., additional, Wege, H., additional, Breder, V., additional, Gabrail, N., additional, Vasseur, B., additional, Attali, P., additional, and Blanc, J.-F., additional

Published
2015
Full Text
View/download PDF

70. P0794 : Relationship between HCV genotype, liver co-morbidities and fibrosis in the French cohort ANRS CO22 HEPATHER

Author

Carrat, F., primary, Haour, G., additional, Fontaine, H., additional, Dorival, C., additional, Simony, M., additional, Bourlière, M., additional, Capeau, J., additional, Carrieri, P., additional, Larrey, D., additional, Larsen, C., additional, Marcellin, P., additional, Pawlotsky, J.-M., additional, Trinchet, J.-C., additional, Zoulim, F., additional, Cacoub, P., additional, De Ledinghen, V., additional, Dubuisson, J., additional, Mathurin, P., additional, Negro, F., additional, Pageaux, G.-P., additional, Yazdanpanah, Y., additional, Wittkop, L., additional, Jean-Pierre, Z., additional, and Pol, S., additional

Published
2015
Full Text
View/download PDF

71. P1266 : Human albumin use in cirrhotic patients in France: Results of the national “Albu-live” survey

Author

Garioud, A., primary, Cadranel, J.-F., additional, Pauwels, A., additional, Thévenot, T., additional, Louvet, A., additional, Dao, T., additional, Sogni, P., additional, Talbodec, N., additional, Bureau, C., additional, Thabut, D., additional, Elkrief, L., additional, Jouannaud, V., additional, Macaigne, G., additional, Bernard-Chabert, B., additional, Lison, H., additional, Alric, L., additional, Carbonnel, N., additional, Pageaux, G.-P., additional, Bettan, L., additional, Labadie, H., additional, Nahon, P., additional, Bader, R., additional, Zarski, J.-P., additional, Abergel, A., additional, Pol, S., additional, Pariente, A., additional, Amiot, X., additional, Mathurin, P., additional, Ollivier-Hourmand, I., additional, Bismuth, M., additional, Dupont, K., additional, Rosa-Hézode, I., additional, Lesgourgues, B., additional, Leroy, V., additional, Poynard, T., additional, Causse, X., additional, Chazouillères, O., additional, Valla, D., additional, Zanditenas, D., additional, Renou, C., additional, Trinchet, J.-C., additional, Paupard, T., additional, Ouzan, D., additional, Guyader, D., additional, Fontanges, T., additional, Hanslik, B., additional, De Lédinghen, V., additional, and Denis, J., additional

Published
2015
Full Text
View/download PDF

72. P0804 : Efficacy of sofosbuvir-based treatment regimens in HIV/HCV co-infected patients after liver transplantation: The ANRS CO23 CUPILT study

Author

Antonini, T.M., primary, Coilly, A., additional, Radenne, S., additional, Veislinger, A., additional, Botta-Fridlund, D., additional, Durand, F., additional, Houssel-Debry, P., additional, Kamar, N., additional, Canva, V., additional, Perre, P., additional, Bertucci, I., additional, Dumortier, J., additional, Leroy, V., additional, Samuel, D., additional, Pageaux, G.-P., additional, and Duclos-Vallee, J.-C., additional

Published
2015
Full Text
View/download PDF

74. P0795 : Safety and efficacy of sofosbuvir-containing regimens in the French observational cohort ANRS CO22 HEPATHER

Author

De Ledinghen, V., primary, Fontaine, H., additional, Dorival, C., additional, Bourlière, M., additional, Larrey, D., additional, Marcellin, P., additional, Lucier, S., additional, Petrov-Sanchez, V., additional, Diallo, A., additional, Capeau, J., additional, Carrieri, P., additional, Larsen, C., additional, Pawlotsky, J.-M., additional, Trinchet, J.-C., additional, Zoulim, F., additional, Cacoub, P., additional, Dubuisson, J., additional, Mathurin, P., additional, Negro, F., additional, Pageaux, G.-P., additional, Yazdanpanah, Y., additional, Wittkop, L., additional, Zarski, J.-P., additional, Carrat, F., additional, and Pol, S., additional

Published
2015
Full Text
View/download PDF

75. G15 : The association of sofosbuvir and daclatasvir for treating severe recurrence of HCV infection after liver transplantation: Results from a large french prospective multicentric ANRS CO23 CUPILT cohort

Author

Coilly, A., primary, Fougerou, C., additional, De Ledinghen, V., additional, Houssel-Debry, P., additional, Duvoux, C., additional, Di Martino, V., additional, Radenne, S., additional, Kamar, N., additional, D’Alteroche, L., additional, Leroy, V., additional, Canva, V., additional, Lebray, P., additional, Moreno, C., additional, Dumortier, J., additional, Silvain, C., additional, Besch, C., additional, Perre, P., additional, Botta-Fridlund, D., additional, Anty, R., additional, Rohel, A., additional, Renault, A., additional, Danjou, H., additional, Duclos-Vallee, J.-C., additional, and Pageaux, G.-P., additional

Published
2015
Full Text
View/download PDF

76. P0468 : Negative impact of HBV/HCV coinfection on HBV or HCV monoinfection: Data from the French cohort – ANRS CO22 hepather

Author

Pol, S., primary, Lucier, S., additional, Fontaine, H., additional, Dorival, C., additional, Petrov-Sanchez, V., additional, Bourlière, M., additional, Capeau, J., additional, Carrieri, P., additional, Larrey, D., additional, Larsen, C., additional, Marcellin, P., additional, Pawlotsky, J.-M., additional, Trinchet, J.-C., additional, Zoulim, F., additional, Cacoub, P., additional, De Ledinghen, V., additional, Dubuisson, J., additional, Mathurin, P., additional, Negro, F., additional, Pageaux, G.-P., additional, Yazdanpanah, Y., additional, Wittkop, L., additional, Zarski, J.-P., additional, and Carrat, F., additional

Published
2015
Full Text
View/download PDF

77. O109 : Treatment of severe HCV-recurrence after liver transplantation using sofosbuvir-based regimens: The ANRS CO23 CUPILT study

Author

Dumortier, J., primary, Botta-Fridlund, D., additional, Coilly, A., additional, Leroy, V., additional, Fougerou-Leurent, C., additional, Danjou, H., additional, Radenne, S., additional, Durand, F., additional, Kamar, N., additional, di Martino, V., additional, de Ledinghen, V., additional, Houssel-Debry, P., additional, d’Alteroche, L, additional, Duvoux, C., additional, Conti, F., additional, Canva, V., additional, Diallo, A., additional, Rohel, A., additional, Duclos-Vallée, J.-C., additional, and Pageaux, G.-P., additional

Published
2015
Full Text
View/download PDF

78. LP23 : Daclatasvir plus sofosbuvir with or without ribavirin in patients with HIV–HCV co-infection: interim analysis of a French multicenter compassionate use program

Author

Fontaine, H., primary, Lacombe, K., additional, Dhiver, C., additional, Rosenthal, E., additional, Metivier, S., additional, Antonini-Michelle, T., additional, Valantin, M.A., additional, Cotte, L., additional, Botero, J., additional, Harent, S., additional, Batisse, D., additional, Pageaux, G.-P., additional, Aumaitre, H., additional, Dominguez, S., additional, De Ledinghen, V., additional, Leroy, V., additional, Dabis, F., additional, Wittkop, L., additional, Filipovics, A., additional, Barlet, M.H., additional, Bennai, Y., additional, and Salmon, D., additional

Published
2015
Full Text
View/download PDF

79. P0137 : Safety of boceprevir-based triple therapy in HCV cirrhotic patients awaiting liver transplantation. Analysis from a French multicenter, open-label study (ANRS HC29 bocepretransplant)

Author

Fontaine, H., primary, Maynard-Muet, M., additional, Bouix, C., additional, Botta-Fridlund, D., additional, D’Alteroche, L., additional, Conti, F., additional, Pageaux, G.-P., additional, Leroy, V., additional, Métivier, S., additional, Anty, R., additional, Durand, F., additional, Canva, V., additional, Lebray, P., additional, Alric, L., additional, Duvoux, C., additional, Petrov-Sanchez, V., additional, Beaulieux, F., additional, Willems, C., additional, Paul, C., additional, Pradat, P., additional, Duclos-Vallée, J.-C., additional, and Samuel, D., additional

Published
2015
Full Text
View/download PDF

80. Author's reply

Author

Aguilar-Martinez, P., Thelcide, C., Schved, J.F., Bismuth, M., Pageaux, G.-P., Blanc, P., Larrey, D., Picot, M.C., and Blanc, F.

Subjects
Health
Abstract

Gyorffy et al calculated Hardy-Weinberg equilibrium (HWE) using data from our paper on H63D homozygotes. (1) They stated that HWE was fulfilled in the control but not in the patient [...]

Published
2004

81. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results

Author

Schiff E., Lai C. -L., Hadziyannis S., Nuehaus P., Terrault N., Colombo M., Tillmann H., Samuel D., Zuezem S., Villenueve J. -P., Arteburn S., Borroto-Esoda K., Brosgart C., Chuck S., Shakil A. O., Fung J., Alberti A., Lok A., Picciotto A., Torre F., Riely C., Trepo C., Bizollon T., Bottaa-Fridlund D., Gerolami R., Douglas D., Ranjan D., Faust D., Trojan J., Gane E., Villa E., Boarino M., Sokal E., Starkel P., Bonino F., Maurizio B., Gordon F., Pratt J., Berr F., Schiefke I., McCaughan G., Strasser S., Dusheiko G., Pageaux G. P., Larrey D., Pastore G., Santantonio T., Alexander G., Woodall T., Van Vlierberghe H., Colle I., Harley H., Guggenheim J., Myx-Staccini A., Metreau J. M., Mavier P., Vierling J., Tran T., Girgrah N., Nyberg L., Yuen M. -F., Ma M., Balnco M. D., Merli M., Tanzilli P., Angelico M., Di Paolo D., Rizzetto M., Marzano A., Lampertico P., Prieto M., Berenguer M., Felder M., Sterneck M., Willems M., Charlton M., Gunneson T., Ritter M., Voight M., Swift J., Shiffman M., Tassopoulos N., Klissas I., Naourmov N., Chamouard P., Marcellin P., Durand F., Angus P., Nathan C., Toniutto P., Fumo E., Andreone P., Cursaro C., Barcena R., Hoz F. G., Zachoval R., Christina M., De Man R. A., Metselaar H., Fagiuoli S., Schiff, E, Lai, C, Hadziyannis, S, Nuehaus, P, Terrault, N, Colombo, M, Tillmann, H, Samuel, D, Zuezem, S, Villenueve, J, Arteburn, S, Borroto-Esoda, K, Brosgart, C, Chuck, S, Shakil, A, Fung, J, Alberti, A, Lok, A, Picciotto, A, Torre, F, Riely, C, Trepo, C, Bizollon, T, Bottaa-Fridlund, D, Gerolami, R, Douglas, D, Ranjan, D, Faust, D, Trojan, J, Gane, E, Villa, E, Boarino, M, Sokal, E, Starkel, P, Bonino, F, Maurizio, B, Gordon, F, Pratt, J, Berr, F, Schiefke, I, Mccaughan, G, Strasser, S, Dusheiko, G, Pageaux, G, Larrey, D, Pastore, G, Santantonio, T, Alexander, G, Woodall, T, Van Vlierberghe, H, Colle, I, Harley, H, Guggenheim, J, Myx-Staccini, A, Metreau, J, Mavier, P, Vierling, J, Tran, T, Girgrah, N, Nyberg, L, Yuen, M, Ma, M, Balnco, M, Merli, M, Tanzilli, P, Angelico, M, Di Paolo, D, Rizzetto, M, Marzano, A, Lampertico, P, Prieto, M, Berenguer, M, Felder, M, Sterneck, M, Willems, M, Charlton, M, Gunneson, T, Ritter, M, Voight, M, Swift, J, Shiffman, M, Tassopoulos, N, Klissas, I, Naourmov, N, Chamouard, P, Marcellin, P, Durand, F, Angus, P, Nathan, C, Toniutto, P, Fumo, E, Andreone, P, Cursaro, C, Barcena, R, Hoz, F, Zachoval, R, Christina, M, De Man, R, Metselaar, H, and Fagiuoli, S

Subjects
Male, medicine.medical_treatment, Liver transplantation, medicine.disease_cause, Gastroenterology, lamivudine-resistant, chemistry.chemical_compound, antiviral therapy, Secondary Prevention, Adefovir, Prospective Studies, Adefovir dipivoxil, medicine.diagnostic_test, liver transplantation, Lamivudine, Middle Aged, Hepatitis B, Drug Therapy, Combination, Female, Kidney Diseases, medicine.drug, Adult, medicine.medical_specialty, Waiting Lists, Adenine, Antiviral Agents, DNA, Viral, Drug Resistance, Viral, Hepatitis B virus, Humans, Liver Transplantation, Organophosphonates, Bilirubin, Internal medicine, medicine, wait-listed, hepatitis B virus, Prothrombin time, Transplantation, Hepatology, business.industry, medicine.disease, chemistry, Immunology, Surgery, hepatitis B, business
Abstract

Wait-listed (n = 226) or post-liver transplantation (n = 241) chronic hepatitis B (CHB) patients with lamivudine-resistant hepatitis B virus (HBV) were treated with adefovir dipivoxil for a median of 39 and 99 weeks, respectively. Among wait-listed patients, serum HBV DNA levels became undetectable (

Published
2007

82. The negative impact of HBV/ HCV coinfection on cirrhosis and its consequences.

Author

Pol, S., Haour, G., Fontaine, H., Dorival, C., Petrov‐Sanchez, V., Bourliere, M., Capeau, J., Carrieri, P., Larrey, D., Larsen, C., Marcellin, P., Pawlostky, J.‐M., Nahon, P., Zoulim, F., Cacoub, P., Ledinghen, V., Mathurin, P., Negro, F., Pageaux, G.‐P., and Yazdanpanah, Y.

Subjects
MIXED infections, HEPATITIS B, HEPATITIS C, CIRRHOSIS of the liver, HYPERTENSION
Abstract

Background Hepatitis B virus (HBV)/hepatitis C virus (HCV) confection has been rarely studied in nonasian series. Aim To compare the characteristics of HBV/HCV coinfected patients to those of HBV- or HCV-monoinfected patients in the ANRS CO22 HEPATHER cohort study. Patients and Methods Of the 20 936 included patients, 95 had HBV/ HCV coinfection (hepatitis B surface antigen, anti- HCV antibody and HCV RNA positive) and were matched with 375 HBV- and 380 HCV-monoinfected patients on age, gender and time since HBV or HCV diagnosis. Results F3-F4 fibrosis was more frequent in coinfected patients (58%) than in HBV- (32%, P < .0001), but similar in HCV-monoinfected patients (52%, P = .3142). Decompensated cirrhosis was more frequent in coinfected patients (11%) than in HBV- (2%, P = .0002) or HCV- (4%, P = .0275) monoinfected patients. Past excessive alcohol use was more frequent in coinfected patients (26%) than in HBV (12%, P = .0011), but similar in HCV monoinfected patients (32%, P = .2868). Coinfected patients had a higher proportion with arterial hypertension (42%) than HBV- (26%) or HCV-monoinfected patients (25%) ( P < .003). Multivariable analysis confirmed the association between F3-F4 fibrosis and HCV infection in HBV-infected patients ( OR = 3.84, 95% CI 1.99-7.43) and the association between decompensated cirrhosis and coinfection in HBV infected ( OR = 5.58, 95% CI 1.42-22.0) or HCV infected patients ( OR = 3.02, 95% CI 1.22-7.44). Conclusions HCV coinfection harmfully affects liver fibrosis in HBV patients, while decompensated cirrhosis is increased in coinfected patients compared with HBV- or HCV-monoinfected patients. HCV treatment is as safe and effective in coinfected as monoinfected patients and should be considered following the same rules as HCV monoinfected patients. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

83. Safety of Anti-TNF Treatment in Liver Transplant Recipients: A Systematic Review and Metaanalysis.

Author

van Meeteren, M. J. Westerouen, Hayee, B., Inderson, A., van der Meulen, A. E., Altwegg, R., van Hoek, B., Pageaux, G. P., Stijnen, T., Stein, D., and Maljaars, P. W. J.

Abstract

Background and Aim: Little is known about the risk of serious infection when combining antitumour necrosis factor [TNF] therapy for refractory inflammatory bowel disease [IBD] with immunosuppression after liver transplantation [LT]. Our aim was to investigate the infection risk in this patient group by systematic review and meta-analysis of the available data. Methods: A search was conducted for full papers and conference proceedings through September 2015, regarding liver transplant recipients and anti-TNF therapy. All studies were appraised using the adapted Newcastle-Ottawa Scale [NOS]. Two reviewers independently extracted patient data [age, duration of follow-up, number of all infections, number of serious infections, time since transplant]. As an additional control population, primary sclerosing cholangitis [PSC]-IBD patients from the Leiden University Medical Center [LUMC] LT cohort were used. Poisson regression was used to compare serious infections (according to International Conference on Harmonisation [ICH] definition) per patien-year follow-up between the anti-TNF and control groups. Results: In all 465 articles and abstracts were identified, of which eight were included. These contained 53 post-LT patients on anti-TNF therapy and 23 post-LT patients not exposed to anti- TNF therapy. From the LUMC LT-cohort, 41 PSC patients with PSC-IBD not exposed to anti-TNF therapy were included as control population. The infection rate for TNF-exposed patients was 0.168 serious infections per patient year, compared with 0.149 in the control patients (rate ratio 1.12 [95% confidence interval: 0.233-5.404, P = 0.886]. When correcting for time since transplant, the infection rate was 0.194 in the TNF-exposed vs 0.115 in the non-exposed [p = 0.219]. Conclusions: No significant increase in the rate of serious infection was observed in LT recipients with PSC-IBD during exposure to anti-TNF therapy. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

85. P1062 3-YEAR TREATMENT WITH TENOFOVIR IN REAL-LIFE IS EFFECTIVE AND WELL TOLERATED IN CHB PATIENTS, INCLUDING THE ELDERLY AND PATIENTS WITH COMORBIDITIES

Author

Causse, X., primary, Pageaux, G.-P., additional, Zoulim, F., additional, Larrey, D., additional, Ouzan, D., additional, Truchi, R., additional, Pauwels, A., additional, Guyader, D., additional, De Ledinghen, V., additional, Tilliet, V., additional, Cadranel, J.-F., additional, Stern, C., additional, Libert, O., additional, and Marcellin, P., additional

Published
2014
Full Text
View/download PDF

86. O85 SHOULD WE AWAIT INTERFERON-FREE REGIMENS TO TREAT HCV GENOTYPE 1 TREATMENT-NAIVE PATIENTS? A COST-EFFECTIVENESS ANALYSIS (ANRS 12188)

Author

Deuffic-Burban, S., primary, Schwarzinger, M., additional, Obach, D., additional, Mallet, V., additional, Pol, S., additional, Pageaux, G.-P., additional, Canva, V., additional, Deltenre, P., additional, Roudot-Thoraval, F., additional, Larrey, D., additional, Dhumeaux, D., additional, Mathurin, P., additional, and Yazdanpanah, Y., additional

Published
2014
Full Text
View/download PDF

87. P1061 LONG-TERM TREATMENT WITH TENOFOVIR IN TREATMENT-NAIVE OR -EXPERIENCED CHB PATIENTS IS EFFECTIVE AND WELL TOLERATED IN REAL-LIFE PRACTICE: 3 YEARS RESULTS OF THE VIREAL STUDY

Author

Pageaux, G.-P., primary, Zoulim, F., additional, Causse, X., additional, Larrey, D., additional, Ouzan, D., additional, Truchi, R., additional, Pauwels, A., additional, Guyader, D., additional, De Ledinghen, V., additional, Zarski, J.-P., additional, Cadranel, J.-F., additional, Tilliet, V., additional, Stern, C., additional, Libert, O., additional, and Marcellin, P., additional

Published
2014
Full Text
View/download PDF

90. Choix du dénominateur pour les études cas-population : taux d’insuffisance hépatique aiguë ayant conduit à l’inscription sur la liste de transplantation hépatique chez des patients exposés à des anti-inflammatoires non stéroïdiens en France et inclus dans l’étude SALT

Author

Moore, N., primary, Ezgi Gulmez, S., additional, Larrey, D., additional, Pageaux, G.-P., additional, Lignot, S., additional, Lassalle, R., additional, Jové, J., additional, Pariente, A., additional, Blin, P., additional, Bénichou, J., additional, and Bégaud, B., additional

Published
2014
Full Text
View/download PDF

92. SAT-149 - Ledipasvir/Sofosbuvir in NS3/4A Protease Inhibitor-Experienced Subjects with HCV Genotype 1 and HIV-Co-Infection Final Results of the ANRS HC31 Softrih Study

Author

Rosenthal, E., Fougerou-Leurent, C., Renault, A., Teicher, E., Dominguez, S., Naqvi, A., Metivier, S., Cotte, L., Reynes, J., Valantin, M.-A., Leroy, V., Pageaux, G.-P., Pol, S., Piroth, L., Perre, P., Morlat, P., Salmon-Ceron, D., Chas, J., Jeantils, V., de Truchis, P., Allègre, T., Dupon, M., Raffi, F., Yazdanpanah, Y., Poizot-Martin, I., Neau, D., Girard, P.-M., Zucman, D., Garraffo, R., Chevaliez, S., Carrieri, P., Aumaitre, H., Lacombe, K., Bailly, F., Billaud, E., Pailhé, A., Amri, I., Bourlière, M., Bellissant, E., and Molina, J.-M.

Published
2016
Full Text
View/download PDF

93. SAT-131 - Sustained Virologic Response to Daclatasvir and Sofosbuvir, with or without Ribavirin, among Patients in the French Daclatasvir ATU Programme Infected with HCV Genotypes 4, 5 and 6

Author

Hézode, C., Abergel, A., Chas, J., Conti, F., Cotte, L., Tateo, M., Alric, L., Vergniol, J., Tomei, C., Bernard, P.-H., Loustaud-Ratti, V., Arpurt, J.-P., Blaison, D., Larrey, D., Fedchuk, L., Bennai, Y., Filipovics, A., Fontaine, H., and Pageaux, G.-P.

Published
2016
Full Text
View/download PDF

94. FRI-481 - Renal Dysfunction in Liver Transplant Patients Treated with Sofosbuvir Based-Regimen for HCV Recurrence: Results from a Large French Prospective Multicentric ANRS CO23 Cupilt

Author

Anty, R., Coilly, A., Fougerou, C., De Ledinghen, V., Houssel-Debry, P., Duvoux, C., Di Martino, V., Radenne, S., Kamar, N., D’Alteroche, L., Canva, V., Lebray, P., Moreno, C., Dumortier, J., Silvain, C., Besch, C., Botta-Fridlund, D., Leroy, V., Durand, F., Tran, A., Montialoux, H., Habersetzer, F., Favre, G., Rossignol, E., Rohel, A., Renault, A., Dharancy, S., Danjou, H., Duclos-Vallee, J.-C., and Pageaux, G.-P.

Published
2016
Full Text
View/download PDF

95. FRI-483 - Sofosbuvir-Based-Regimen for HCV Recurrence after Combined Liver-Kidney Transplantation : Results from the ANRS CO23 Cupilt Study

Author

Dharancy, S., Coilly, A., Fougerou-Leurent, C., Duvoux, C., Kamar, N., Leroy, V., Tran, A., Houssel-Debry, P., Canva, V., Moreno, C., Conti, F., Dumortier, J., Di Martino, V., Radenne, S., De Ledinghen, V., D’Alteroche, L., Silvain, C., Besch, C., Perré, P., Botta-Fridlund, D., Francoz, C., Habersetzer, F., Montialoux, H., Abergel, A., Debette-Gratien, M., Rohel, A., Vallée, J.C.D., and Pageaux, G.-P.

Published
2016
Full Text
View/download PDF

96. FRI-449 - Does Multiorgan Failure Impact Prognosis of Liver Transplantation in Patients with End-Stage Liver Disease? Results of a French Retrospective Multicenter Case-Control Study

Author

Artru, F., Louvet, A., Ruiz, I., Levesque, E., Labreuche, J., Jaber, S., Lassailly, G., Dharancy, S., Boleslawski, E., Lebuffe, G., Kipnis, E., Ichai, P., Coilly, A., De Martin, E., Vibert, E., Herrerro, A., Samuel, D., Pageaux, G.-P., Mathurin, P., and Saliba, F.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results